Orthofix Medical Inc

The asset remains in a Stage 4 decline with confirmed lower highs and lower lows under declining EMAs. Price has been rejected at the 9/20 EMA band repeatedly, reinforcing a medium-term bearish bias. Oversold status does not grant mean-reversion permission, and short-term timing is neutral. Execution should be deferred into future rally attempts into EMA resistance rather than sold immediately. A Trim is recommended to seek a better entry point on a bounce into the EMAs.

• ↑Q2 EPS of $0.07 beats est; revenue $210.9M (+4% YoY).
• ↑Global Spine Fixation and Limb Reconstruction segments up double digits.
• ↓Q2 net loss widened to $15.8M despite revenue gains.